Clinical Trial Update: Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating FCN-437c in combination with fulvestrant or letrozole+goserelin for breast neoplasms (breast cancer) with efficacy, safety, and PK data…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FCN-437c
• Fulvestrant (fulvestrant)
• Goserelin (Goserelin)
• Letrozole (letrozole)

Snippet

Sponsor: Ahon Pharmaceutical Co., Ltd. | Conditions: Breast Neoplasms | Phase 2 | Status: UNKNOWN